The currently developed CDK4/6 inhibitors, such as ribociclib, oalbociclib and abemaciclib, are mainly used to treat ER+/HER2− breast cancer and can significantly prolong the PFS of patients [47]. The gene discussed is CDK4; the disease is breast carcinoma.